Assoc Prof Dr. Chen Wang | Anti-tumor Nanomaterials | Best Researcher Award

Assoc Prof Dr. Chen Wang | Anti-tumor Nanomaterials | Best Researcher Award

Guangxi Medical University Cancer Hospital | China

Author Profile

Scopus

Orcid id

šŸŒŸ Distinguished Scientist Award: Dr. Chen Wang šŸŒŸ

Full Name: Chen Wang
Gender: Male
Designation: Associate Research Fellow
Department: Guangxi Key Laboratory of Basic and Translational Research for Colorectal Cancer
Institution/Organization: Guangxi Medical University Cancer Hospital
Qualification: Ph.D.
Area of Specialization: Oncology Therapeutics and Novel Approaches
Sub Division: Anti-tumor Nanomaterials

šŸ“š Education and Experience

Born in Liaoning, China, in 1988, Dr. Chen Wang has dedicated his career to advancing cancer treatment through innovative research in materials science and engineering. He earned his BS (2010) and MS (2013) degrees from Shenyang University of Technology, followed by a Ph.D. from Harbin Engineering University in 2019. Dr. Wang’s postdoctoral research took place at the Changchun Institute of Applied Chemistry and Southern Medical University. He began his academic career at Jilin University of Chemical Technology and joined Guangxi Medical University Cancer Hospital in 2020, becoming an associate research fellow in 2022.

šŸ§¬ Research and Innovations

Dr. Wang specializes in the synthesis and clinical application of novel anti-tumor nanomaterials. His pioneering work on calcium overload as a novel treatment for tumor cells has garnered significant attention. The development of GMCP (GOx@MMPB@CaP-PEG) nanoparticles showcases his innovative approach, combining enhanced intratumor reactive oxygen species (ROS) levels with photothermal therapy to promote apoptosis in tumor cells.

šŸ† Achievements

  • Publications: Nearly 30 SCI-indexed original articles, including 11 as first/corresponding author.
  • Projects: Completed 12 research projects, with 5 as the principal investigator.
  • Patents: Holds 7 patents.
  • Editorial Roles: Serves on the editorial boards and as a reviewer for multiple journals.
  • Memberships: Member of the China Food and Drug Enterprise Quality and Safety Promotion Association.
  • Citations: 495 citations in Scopus/Web of Science.
  • H-index: 13.
  • Impact Factor: Cumulative impact factor of 141.8 over the last three years.

Dr. Wang’s work in oncology therapeutics, particularly in anti-tumor nanomaterials, positions him as a leading figure in his field, making him a deserving recipient of the Distinguished Scientist Award.

šŸŒ Professional Links

šŸ“„ Certifications

  • Education Proof (Ph.D.): 1021722019110003
  • Government ID (Passport): E36369406

Dr. Chen Wang’s dedication to research, innovation, and the application of novel cancer treatments underscores his significant contributions to the field of oncology therapeutics.

 

šŸ“ŠšŸ”¬Notable Publication:

 

 

 

 

Prof. IsabellaCavalcanti – Cancer Science – Best Researcher Award

Prof. IsabellaCavalcanti - Cancer Science - Best Researcher Award

Federal University of Pernambuco (UFPE) - Brazil

Author Profile

Google ScholarĀ 

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Isabella MacƔrio Ferro Cavalcanti began her academic journey by graduating in Biomedicine from the Federal University of Pernambuco (UFPE). Following this, she pursued a master's degree in Therapeutic Innovation at UFPE, delving into advanced studies in the field. She then proceeded to earn her doctorate in Biotechnology, further refining her expertise in biological sciences.

PROFESSIONAL ENDEAVORS

Dr. Cavalcanti's professional career has been marked by significant accomplishments. She specializes in Clinical Microbiology, obtaining further specialization at the University of Pernambuco (UPE). Currently, she serves as a professor at UFPE, where she contributes to the education and training of future professionals in the field. Her involvement extends to leadership roles within various post-graduate programs, emphasizing her dedication to academic advancement.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER SCIENCE

Dr. Cavalcanti's research endeavors are diverse and impactful. As the Head and Researcher of Clinical Microbiology at the Laboratory of Immunopathology Keizo Asami at UFPE (LIKA/UFPE), she spearheads investigations into drug delivery systems and their biological activities. Her research group, MicroNAT, focuses on innovative approaches to combat multi-drug-resistant bacteria and biofilm formation. Through her work, she seeks to advance pharmaceutical nanotechnology and fundamental microbiological understanding.

IMPACT AND INFLUENCE

Isabella MacƔrio Ferro Cavalcanti's contributions have had a profound impact on the fields of pharmaceutical nanotechnology and microbiology. Her research findings contribute to the development of novel therapeutic strategies and the understanding of microbial resistance mechanisms. As a respected member of the Brazilian Society of Microbiology and various scientific committees, her expertise is recognized nationally and internationally.

ACADEMIC CITATIONS

Dr. Cavalcanti's work has garnered significant attention within the academic community, reflected in numerous citations of her research publications. Her contributions to scientific literature serve as a foundation for further exploration and innovation in the fields of biotechnology, microbiology, and drug delivery.

LEGACY AND FUTURE CONTRIBUTIONS

With a strong foundation in academia and research, Dr. Cavalcanti's legacy is marked by her dedication to advancing knowledge and addressing critical healthcare challenges. Her leadership in research groups and academic programs ensures the continued development of future scientists and the pursuit of innovative solutions to complex biomedical problems. As she continues her career, her contributions are poised to further shape the landscape of biomedicine and microbiology, leaving a lasting legacy of excellence and innovation.

NOTABLE PUBLICATIONS

Zein nanoparticles containing ceftazidime and tobramycin: antibacterial activity against Gram-negative bacteria. 2024

Proteomic characterization and biological activities of the mucus produced by the zoanthid Palythoa caribaeorum (Duchassaing & Michelotti, 1860) 2023

Efficacy and non-toxicity of ciclopirox olamine-loaded liposomes against Cryptococcus neoformans clinical isolates. 2023

Gram-negative bacilli carrying mcr gene in Brazil: a pathogen on the rise. 2023

Antibiotic resistance profiles on pathogenic bacteria in the Brazilian environments. 2023

Mr.Christopher Olowosoke – Targeted Cancer Therapy – Best Researcher Award

Mr.Christopher Olowosoke - Targeted Cancer Therapy - Best Researcher Award

Federal University of Technology Akure - Nigeria

AUTHOR PROFILE

Scopus

EARLY ACADEMIC PURSUITS

Christopher Busayo Olowosoke embarked on his academic journey with a focus on biotechnology. His dedication to academic excellence was evident during his West African Senior School Certificate Examination at Isefun Community Senior Secondary School, Lagos State, Nigeria, where he achieved a grade of Distinction in the Science stream. This early success set the stage for his future pursuits in the field of biotechnology and information technology.

PROFESSIONAL ENDEAVORS

With a passion for biotechnology and an interest in the chemistry of natural products and pharmacology, Christopher pursued his first degree at the Federal University of Technology, Akure, Ondo State, Nigeria. Graduating with an outstanding grade of 4.73/5.00 in Biotechnology in 2020, he showcased his commitment to academic excellence. His undergraduate thesis, "Identification of pungency-associated genes in some indigenous Nigerian hot pepper varieties," demonstrated his engagement with cutting-edge research.

CONTRIBUTIONS AND RESEARCH FOCUS ON TARGETED CANCER THERAPY

As a Student Research Assistant at the Federal University of Technology, Akure, Christopher actively contributed to research in the Departments of Biochemistry, Biotechnology, and Microbiology from 2017 to 2021. His involvement in in vivo, in vitro, and in silico procedures for diabetes andĀ  targeted cancer therapy underscored his commitment to addressing metabolic and cellular proliferation dysregulation, aligning with Sustainable Development Goal 3 (SDG 3). Additionally, his work on the phyto-treatment of diabetes using Andrographic paniculata showcased his dedication to innovative therapeutic approaches.

IMPACT AND INFLUENCE

Christopher's impact extended beyond the laboratory. As a Laboratory Research Assistant at Chrisland University Biotechnology Department from 2022 to the present, he played a pivotal role in organizing practical sessions and providing training in bioinformatics and molecular biology for undergraduates. His leadership as the Founder of B.Khrease Academic Consult since 2018 highlights his commitment to facilitating student projects, mentorship, and collaboration with academic experts.

ACADEMIC CITES

Christopher's research contributions are recognized through his publications. His paper titled "Multiregulator of EZH2-PPARs Therapeutic Targets" was published in Applied Biochemistry and Biotechnology in 2023. This publication addresses critical aspects of pancreatic insulin production and cancer dysregulation. The link to his full publication list on ResearchGate (https://www.researchgate.net/profile/Christopher-Olowosoke/research) reflects his ongoing scholarly pursuits.

LEGACY AND FUTURE CONTRIBUTIONS

Christopher's legacy includes leadership roles, such as being the Founder of B.Khrease Academic Consult and serving as the Promotional and Development Committee Head at the Institute of Bioinformatics and Molecular Therapeutic (IBMT) since 2021. His active participation in conferences, workshops, and professional webinars, as well as affiliations with prestigious societies, showcases his commitment to staying at the forefront of biotechnological advancements.

AWARDS/GRANT

Christopher's achievements are acknowledged through various awards and grants, including being a beneficiary of the American Society for Nutrition Early Career Professional Mentoring Program in 2023 and securing the second position in the Peeref International Best Poster Presentation in the same year. His involvement in securing the TETFUND Grant Award for the Biotechnology Department in 2022 and the UNESCO-ICB Scholarship in 2020 further demonstrates his capacity to contribute significantly to his field.

NOTABLE PUBLICATION

Multi-regulator of EZH2-PPARs Therapeutic Targets: A Hallmark for Prospective Restoration of Pancreatic Insulin Production and Cancer Dysregulation.